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ABSTRACT (241 words) 
Objective: To identify proteins related to intraluminal thrombus (ILT) biological 
activities that could help to find novel pathological mechanisms and/or therapeutic 
targets for human abdominal aortic aneurysm (AAA).  
Methods and results: Tissue-conditioned media from AAA patients were analyzed by 
a mass spectrometry (MS)-based strategy, using liquid chromatography coupled to 
tandem MS (LC-MS/MS). Global pathways analysis by Ingenuity software 
highlighted the presence of several circulating proteins, among them proteins from the 
complement system. Complement C3 concentration and activation were assessed in 
plasma from AAA patients [small AAA, AAA diameter = 3-5 cm and large AAA, 
AAA diameter > 5cm], showing decreased C3 levels and activation in large AAA 
patients. No association of a combination of single nucleotide polymorphisms in 
complement genes between large and small AAA patients was observed. Intense 
extracellular C3 inmunostaining, along with C9, was observed in AAA thrombus. 
Analysis of C3 in AAA tissue homogenates and tissue-conditioned media showed 
increased levels of C3 in AAA thrombus, as well as proteolytic fragments 
(C3a/C3c/C3dg), suggesting its local deposition and activation. Finally, the functional 
role of local complement activation in polymorphonuclear (PMN) cell activation was 
tested showing that C3 blockade by antiC3 antibody was able to decrease thrombus-
induced neutrophil chemotaxis and ROS production. 
Conclusion: A decrease of systemic C3 concentration and activity in the later stages 
of AAA associated to local complement retention, consumption and proteolysis in the 
thrombus could induce PMN chemotaxis and activation playing a detrimental role in 
AAA progression.  
Keywords: abdominal aortic aneurysm-complement system-neutrophils-immune 
inflammation-thrombus 
Clinical and pathophysiological evidences indicate that Intraluminal Thrombus (ILT) 
play a role in evolution of Abdominal Aortic Aneurysms (AAA) (1). The eccentric 
distribution of the ILT was associated with continuous expansion (2) and aortic ILT 
volume is associated with AAA growth (3-5). It has been reported that large ILT areas 
were significantly associated with increased AAA expansion (3). Speelman et al 
demonstrated that larger ILT in AAA was associated with a higher AAA growth rate, 
but also with a lower wall stress. These data suggests that weakening of the AAA 
wall, under the biological dynamics of ILT, might play a more imminent role in the 
process of AAA growth than the stress acting on the wall (4). A recent study has 
confirmed the association of ILT volume with AAA growth and also, with 
cardiovascular events (5).  Finally, radiological signs of ILT lysis could precede aortic 
rupture (crescent sign) (1). 
In parallel, accumulating data suggest that biological activities associated to 
leukocyte, platelet and red blood cell accumulation in ILT play an important role in 
AAA progression (6-11). Thus, the identification of novel proteins related to ILT 
biological activities could help to find novel pathogenic mechanisms, as well as 
therapeutic targets, of AAA. In previous studies, following a strategy based on the 
analysis of AAA tissue-conditioned media by gel- or array-based proteomic 
techniques, we identified proteins related to different pathological processes involved 
in AAA such as oxidation (10) and proteolysis (12). In order to explore further the 
pathophysiology of ILT in human AAA increasing the number of identified proteins, 
ILT and wall conditioned-media were analyzed in this study using liquid 
chromatography and tandem MS (LC-MS/MS). Global pathways analysis of 
identified peptides/proteins by Ingenuity software highlighted that complement 
system components were highly enriched in AAA tissue-conditioned media.  
The complement system plays a major role in innate immunity, participating in host 
defense responses against microorganisms via opsonization, chemoattractation of 
leukocytes, cell activation and bridging innate and adaptative immunity (13-16). 
However, disturbances in this defense machinery contribute to the pathogenesis of 
various autoimmune diseases, such as systemic lupus erythematosus (SLE). SLE is 
characterized by decreased circulating complement components associated to their 
deposition and activation in host tissues. As complement proteins are mainly 
synthesized by the liver, we hypothesized that the high levels of complement C3 
peptides/proteins identified in AAA thrombus-conditioned media could be related to 
its trapping from the blood and/or by increased proteolytic activation. To test this 
hypothesis, we first assessed C3 concentration and activity in blood of AAA patients 
at different stage of the disease. Second, we analyzed the presence and activation of 
C3 in AAA tissue and tissue-conditioned media. Finally, we studied the effect of 
complement activation in human AAA thrombus on neutrophil chemotaxis and 




In a first cohort, serum from 62 male patients with an asymptomatic infrarenal AAA 
was collected during clinical examination (aortic size = 3-5 cm, small AAA). 
Additionally, serum from 28 male patients with an asymptomatic infrarenal AAA was 
collected before surgical repair (aortic size > 5 cm, large AAA). Twenty-eight healthy 
male controls with non-dilated infrarenal aortas (aortic size < 3 cm, confirmed with 
abdominal ultrasound) and no risk factors were obtained from a screening program 
undertaken in our area of care. All these samples were obtained from Galdakao 
Ursansolo Hospital (Bilbao, Spain). In a second cohort, plasma samples were 
obtained from the biobank of IIS-FJD (Madrid, Spain) including 26 small AAA 
patients and 39 large AAA patients. Hypertension was defined as systolic blood 
pressure (sBP) >140 mmHg and/or diastolic pressure (dBP) ≥90 mmHg measured 
during the examination, after the participant had been sitting for at least 30 minutes, 
or the participant was already taking hypotensive medication. A patient was 
considered diabetic if he was under treatment (supervised diet, hypoglycaemic oral 
medication, insulin) or we found basal glycaemia >120 mg/dL and/or HbA1c 
>=6.5%. Hypercholesterolemia was defined as total basal cholesterol levels ≥200 
mg/dl, LDL levels ≥100 mg/dl or the patients were receiving specific medication or a 
supervised diet. Cardiac disease included coronary heart disease, valvular disease, 
cardiomyopathy and arrhythmia. Clinical characteristics are summarized in Table 1. 
The studies were approved by Spanish center’s Research and Ethics Committees, and 
informed consent from the patients and the controls for their inclusion in the study 
was obtained.  
Danish patients 
Blood cells were obtained from 186 patients from the randomised population based 
Viborg Vascular  (VIVA) screening trial screening 65-74 year old men for AAA, 
peripheral arterial disease and unrecognised hipertension (17). Informed consent was 
obtained from all subjects before participation, and the study was approved by the 
Local Ethics Committee of the Viborg Hospital, Denmark, and performed in 
accordance with the Helsinki Declaration. Cases were selected according to initial 
size and growth rate. Clinical characteristics of the patients are included in table 1 
online. 
AAA tissue and tissue-conditioned media 
Sixteen AAA thrombus and wall samples were collected from patients enrolled in the 
RESAA protocol (18) undergoing surgery (three for MS analysis, ten for ELISA, 
western-blot and immunohistochemistry and six for homogenization). One part was 
included in paraffin for immunohistochemistry and the rest was dissected into 
thrombus and wall (media and adventitia) for incubation in a RPMI protein-free 
medium. All patients gave their informed written consent and the protocol was 
approved by a French ethics committee (CPB, Cochin Hospital). Twelve control 
aortas (six for immunohistochemistry and six for homogenization) were sampled from 
dead organ donors with the authorization of the French Biomedicine Agency (PFS 09-
007). These control aortic samples were macroscopically normal, devoid of early 
atheromatous lesions. Different layers of AAA thrombus and wall, as well as healthy 
walls, were cut into small pieces (5 mm2) and separately incubated in RPMI 1640 
medium containing antibiotics and an antimycotic (Gibco) for 24 hours at 37°C (6 
ml/g of wet tissue). The conditioned medium (supernatant containing proteins 
released by the tissue sample) was obtained after centrifugation as 3,000 g for 10 
minutes at 20°C. In some cases, native C3 [purified as previously described in 
Alcorlo M et al, (19)] was incubated for 90 min at 37ºC with 1 l of thrombus-
conditioned media and then subjected to western-blot. In addition, tissues were snap-
frozen in N2 liquid and homogenates (0.2 g) were divided and resuspended for mRNA 
and protein analysis. 
NanoLC-MS/MS analysis             
Proteins from AAA–tissue conditioned media from 3 patients were precipitated using 
2D clean-up kit (GE Healthcare) and re-dissolved in Triethylammonium bicarbonate 
(TEAB) buffer. Then, they were analysed by nLC-MS/MS, as described in 
supplemental methods online. 
Quantification of C3 and C3a  
Soluble concentrations of C3 in human plasma samples were automatically measured 
using VITROS chemistry products C3 reagents in the VITROS 5,1 FS and VITROS 
5600 Integrated System analyzers, following the manufacturer´s instructions (Ortho-
Clinical Diagnostics, Johnson & Johnson). Soluble concentrations of C3 in serum 
samples from first cohort or in plasma samples from third cohort were assayed 
automatically by timed nephelometry using a BNII Nephelometer (Siemens9). Both 
methods were standardized against the international reference preparation CRM 470 
(RPPHS). C3 and C3a in conditioned media was measured with commercial kits 
(EC2101 Assaypro and 550499 BD, respectively) following the manufacturer’s 
instructions.  
AP50 assay 
To test the hemolitic capacity of the complement system, red blood cells (RBCs) from 
healthy rabbits were used together with human sera as described (20) (see 
supplemental methods online).  
DNA isolation and genetic study 
Genomic DNA was extracted from peripheral blood using EZ1 DNA Blood 350 μl 
Kit in an EZ1 Advance Robot (Qiagen) following standard procedures. DNA samples 
were genotyped for six single nucleotide polymorphisms (SNPs) (CFH Ile62Val, CFH 
c.1696+2019G>A, CFHR1 Glu175Gln, CFB Leu9His, CFB Arg32Gln/Trp) (21). The 
genotyping was performed using multiplex PCR and minisequencing methodology 
(ABI Snapshot; Applied Biosystems). Minisequecing reations were run in an 
automated sequencer (model 3730; ABI), and the fragments were analyzed with the 
appropriate software (GeneMapper Software 4.0; ABI). 
Immunohistochemistry 
AAA and control aorta samples were fixed in 3.7% paraformaldehyde and embedded 
in paraffin. Immunohistochemistry was performed using antiC3 (purified as described 
in 22) and anti-C9 (mAb B7, a generous gift of Prof. Paul Morgan, Cardiff 
University) as primary antibodies. Negative controls using the corresponding IgG 
were included for checking non-specific staining. The secondary antibody and 
ABComplex/HRP were added and sections were stained with 3,30-diaminobenzidine 
and mounted in DPX. For colocalization of C3 with vascular smooth muscle cells 
(alpha-actin), immunohistochemistry followed by immunofluorescence was 
performed. Colocalization of C3 with CD15/CD68? 
Western blot 
Equal amounts of proteins from tissue or conditioned medium (30 g or 5 L 
previously normalized to tissue weight: 1 g/6 mL, respectively) were loaded onto 
12.5% polyacrylamide gels, electrophoresed and transferred to nitrocellulose 
membranes. Then they were blocked with 7% milk powder in TBS-T for 1 hour and 
incubated overnight at 4ºC with antiC3 (22). Then the membranes were washed with 
TBS-T and incubated with anti-rabbit antibody (1:5000) for 1 hour at RT. After 4 
washes, the signal was detected using the ECL chemiluminiscence kit (GE 
Healthcare). 
Real time PCR  
Total RNA was isolated from cells using TRIzol reagent (Invitrogen). One microgram 
of RNA was used to perform the reverse transcription with the high capacity cDNA 
archive kit (Applied Biosystems). Real-time PCR reactions were performed on an 
ABI Prism 7500 sequence detection PCR system (Applied Biosystems) according to 
the manufacturer’s protocol, using the DDCt method. Human mRNA levels for C3 
and 18S were done by amplification of cDNA using SYBRw Premix Ex TaqTM 
(Takara Biotechnology). The primer sequences are: Forward primer: 
AAGCGCATTCCGATTGAGGA, Reverse primer: 
AAGACTTCCCCACCAGGTCT. The mRNA levels of C3 were normalized to the 
18S mRNA content.  
Cell isolation, chemotaxis assay and ROS production. 
Neutrophils were isolated from venous blood of healthy volunteers and transwell 
migration assays and ROS production were performed as described (12, 23) (see 
supplemental methods online) 
Statistics  
Normality of data was checked by probability plots. Normally distributed C3 
concentrations and activity are expressed as mean±SEM. P < 0.05 was considered to 
be statistically significant. Difference among the groups in the first cohort (control, 
small aaa and large aaa) was analyzed by one-way ANOVA test followed by post hoc 
Tukey Kramer test for multiple comparisons. Differences among the groups of the 
second cohort and third cohort (small AAA vs large AAA) were analyzed by t-test. 
Pearson correlation was used to determine correlations between two variables. 
Logistic or linear regression analysis adjusted by risk factors was conducted with 
AAA stage (small/large AAA) and aortic size as dependent variables, respectively. 
The Wilcoxon paired test was used to analyze differences in C3 and C3a levels 
between thrombus and wall supernatants of the same samples, while non-paired tests 
were used for pathological wall vs healthy wall supernatants comparisons. All the 
statistical analyses were performed by using SPSS 11.0 statistical package. 
RESULTS  
LC-MS/MS analysis of proteins from AAA tissue-conditioned media 
Proteins obtained from AAA thrombus- and wall- conditioned media were trypsin-
digested and the resulting peptides were then fractionated by 2D-LC using a strong 
cation exchange column followed by C18 reversed phase chromatography. Finally, 
the MS and MS/MS spectra were used for protein identification. Table 2 online lists 
all the proteins identified in AAA-tissue supernatants, where a 60% of them were 
classically secreted. To organize identified proteins, Ingenuity software was used to 
find the most enriched canonical pathways in our samples. A total of 257 proteins 
extracted from the protein lists corresponding to thrombus and wall layers 
supernatants were analysed in the same data set. Among others, coagulation and 
complement systems have been found as relatively enriched in the AAA-tissue 
supernatants (as compared with the human genome database) (Figure 1A). 
Interestingly, several complement-related proteins [e.g. C3, C9, clusterin, factor H] 
were identified, which are represented in grey colour on Figure 1B.  
Systemic C3 concentrations and activity in AAA patients 
As C3 is the central molecule in the complement cascade, we analyzed serum 
concentrations of C3 in a first cohort of healthy controls (n = 28) and AAA patients at 
follow-up [small AAA, AAA diameter = 3-5cm (n = 62)] or at surgery [large AAA, 
AAA diameter>5cm, (n=28)]. Increased C3 concentrations were observed in small 
AAA patients compared to both controls and large AAA patients (controls=1485 vs 
small AAA= 1774 vs large AAA= 1248 mg/dl; p<0.01). Logistic regression 
analysis showed that association between increased C3 in small AAA patients vs 
controls remained significant when adjusted by age but was lost when adjusted for 
risk factors (not shown), whereas the decreased C3 in large vs small AAA patients 
persisted after adjustment for risk factors (Table 3 online). Plasma C3 concentrations 
correlated with lipid levels (r = 0.4 for LDL and tryglicerides and r=-0.4 for HDL, 
p<0.001 for all) and aortic size (r= -0.4, p<0.005). Linear regression analysis between 
C3 and aortic size was also independent on risk factors (Table 4 online). 
In order to confirm previous data, we further analyzed in a second cohort of patients, 
showing that large AAA patients (n=39) have significantly decreased C3 plasma 
concentrations compared to small AAA patients (n =26) (1224 vs 1384 mg/dl, 
p<0.01, Figure 2A), which persisted after adjustment for risk factors (Table 3 
online). A non-significant negative correlation was shown for C3 and aortic size (r=   
-0.2, p=0.1, Figure 2C). To test whether complement activity is modified in plasma of 
AAA patients at different stage of evolution, we performed an AP50 assay that 
measure the ability of the patient's plasma to lyse rabbit erythrocytes. Accordingly, 
large AAA patients have decreased complement activity as compared to small AAA 
patients [425 vs 754 % lysis; p<0.01, Figure 2B]. Logistic regression analysis 
showed that the significant association between AP50 in large AAA compared to 
small AAA patients persisted after adjustment for risk factors (Table 3 online). AP50 
correlated with aortic size (r = -0.4, p<0.005, Figure 2D), which persisted after 
adjustment for risk factors (Table 4 online). 
Genetic association study 
No association of SNPs in the complement cascade in AAA patient and control 
studies have been recently described (24,25). To get further insight into a potential 
genetic association between complement and AAA evolution, we analyze whether the 
decrease in C3 concentrations and activity in large vs small AAA patients could be 
related to a particular combination of SNPs in complement genes (“complotypes”), as 
described for other disorders like age-related macular degeneration (reviewed in 
Harris et al, 21). However, no association was found between these complotypes and 
AAA in patients at different stages of the disease (large vs small AAA). In plasma 
samples available from these patients (n = 138), we further confirmed that C3 
concentrations were decreased in large AAA patients (n = 66) compared to small 
AAA patients (n = 72) (1945 vs 2105 mg/dl, p < 0.05). Logistic regression analysis 
showed that the significant association between decreased plasma C3 in large AAA 
compared to small AAA patients persisted after adjustment for risk factors (Table 3 
online). A non-significant negative correlation was shown for C3 and aortic size (r=-
0.2, p=0.07).  
Local complement retention and activation in AAA  
We analyzed the presence of C3 in AAA tissue by immunohistochemistry, showing 
an intense extracellular staining in the ILT and in a lesser extent in the wall, whereas 
healthy wall shows weak staining (Figure 3A). Similarly, high C9 staining was 
observed in AAA thrombus compared to wall and healthy wall (supplemental figure 
1). Interestingly, C3 and C9 deposition was observed in similar areas of the thrombus, 
suggesting complement activation (Figure 3b). Whereas C3 was mainly present in 
acellular areas of the thrombus, C3 in the wall was also associated to alpha-actin 
positive cells in the media (supplemental figure 2) and CD15/CD68 positive cells 
mainly in adventitia (not shown?), suggesting the possible synthesis by resident or 
infiltrating cells in the wall. To test this hypothesis, we performed both real time-PCR 
and western-blot of tissue homogenates. No detectable C3 mRNA was obtained from 
3 out of 6 thrombus analyzed and very low levels were observed in the rest 
(0.01±0.02 a.u.). No differences were observed in C3 mRNA levels between healthy 
and AAA wall (0.22±0.1 vs 0.28±0.05 a.u., not shown). In contrast, C3 protein levels 
in tissue homogenates were higher in ILT compared to pathological wall and healthy 
wall, confirming the results observed by immunohistochemistry (Figure 4A).  
We further tested C3 concentration and activation in the conditioned media of human 
ILT and wall of AAA, as well as in healthy media. C3 levels were increased in the 
AAA thrombus compared to the pathological wall and healthy wall (5.6±0.5 vs 
2.4±0.2 vs 0.9±0.2 µg/ml, p< 0.001 for all comparisons). Moreover, C3 proteolytic 
fragments of 35-40 KDa [corresponding to the molecular weight of C3c/C3dg, figure 
4 A, B, C] appear mainly in tissue and tissue-conditioned media of ILT and to a lesser 
extent in the wall (media and adventitia) of AAA, whereas almost no proteolytic 
fragments were observed in healthy wall. Since complement activation could involve 
proteolytic degradation of C3 by proteases such as plasmin or elastase (13) 
abundantly present in ILT (6,7), we assessed whether proteolysis of C3 in the 
thrombus of AAA could take place ex vivo. In this respect, when native C3 was 
incubated with the luminal part of the thrombus, the 35-40 KDa fragments observed 
in ILT conditioned media were increased (Figure 4D).  
Role of complement activation in AAA thrombus-induced PMN chemotaxis and 
activation 
As we did not observed the first fragment of C3 activation, C3a, by western blot 
probably due to its low molecular weight, we analyzed the presence of C3a in tissue-
conditioned media by ELISA. We have observed that C3a levels are increased in ILT 
compared to wall of AAA and also to healthy wall (p < 0.001 for all comparisons, 
Figure 5A). Moreover, since C3a is involved in PMN chemotaxis and ROS 
production, we address the functional role of complement activation by proteolysis in 
ILT. Neutrophils were allowed to migrate through a filter into a lower chamber 
containing thrombus-conditioned media and the effect of C3 blocking was assessed. 
Neutrophils were attracted by luminal thrombus and C3 blockade by antiC3 antibody 
was able to decrease such effect (p<0.001)(Figure 5B). Similar effect was observed 
when native C3 was used as a positive control (not shown). Moreover, incubation of 
thrombus-conditioned media with fresh neutrophils increased ROS levels, which was 
prevented by antiC3 antibody (Figure 5C). 
DISCUSSION 
In the present paper, the combination of nano-Liquid Chromatography and 
LTQ-Orbitrap MS allowed us to identify larger lists of proteins from AAA-tissue 
conditioned media, as compared to array or gel-based approaches (10, 12). Several 
proteins previously associated to different AAA pathological mechanisms have been 
identified [e.g immune-inflammatory response (clusterin), thrombosis (fibrinogen)]. 
Interestingly, a recent proteomic study has also shown increased levels of clusterin, a 
complement lysis inhibitor able to block the terminal complement cascade, in AAA-
thrombus conditioned media. In contrast, clusterin concentrations were decreased in 
AAA plasma, and the authors suggested that ILT could sequester systemic proteins 
(26). In agreement, the functional distribution of the identified proteins in our study 
has shown an enrichment in circulating proteins (e.g. coagulation and complement 
systems). As complement proteins are mainly synthesized by the liver, we 
hypothesized that the high levels of complement C3 peptides/proteins identified in 
AAA thrombus-conditioned media could be related to its trapping from the blood 
and/or by increased proteolytic activation. We first analyzed C3 concentrations in 
AAA patients and controls. Circulating C3 levels were increased in small AAA 
patients compared to controls probably suggesting an initial hepatic response to 
vascular injury. However, when we performed a multivariate analysis including risk 
factors, no significant differences were observed between small AAA patients and 
controls in agreement with previous data (27), discarding its potential use as a 
diagnostic biomarker. Regarding risk factors, we have observed a positive correlation 
between C3 and lipid levels. Lipids have been previously suggested as a potential 
mechanism leading to complement activation in experimental and human 
hypercholesterolemia (28). Moreover, it has been proposed that IgG is an initial 
mechanism leading to C3 activation in an experimental model of AAA (29) and 
increased IgG concentrations have been recently observed in small AAA patients vs 
controls. However, IgG concentrations decline in large AAA patients (30). In 
agreement, we have shown that C3 concentrations are decreased in large compared to 
small AAA patients, which was independent of different risk factors. In addition, 
when we performed an AP50 assay to test whether complement activity is modified 
during AAA evolution, we showed a negative association of complement activity 
with later stages of disease and with aortic size, independently on risk factors. On the 
whole, our data suggest that systemic C3 increase in the initial phases of AAA 
probably as a response to injury of the wall to increased lipid and/or IgG 
concentrations, while a decrease in systemic complement concentration and activation 
takes place in the later stages of AAA.  
Complement deficiencies (inherited or acquired) could be linked to the development 
of autoimmunity, as shown in systemic lupus erythematous where decreased 
complement components are observed. To check whether genetic anomalies in 
complement genes could take place in AAA evolution, we performed a genetic study 
analyzing a particular combination of SNPs in complement genes (“complotypes”). 
This approach have been also described for other disorders like age-related macular 
degeneration [(reviewed in Harris et al, (21)]. No association on any of the 
combination of SNPs analyzed was found between small and large AAA patients, 
similar to previous studies where those individual SNPs were assessed in AAA 
patients and controls (24,25). It has been suggested that the acquired diminution in 
circulating complement proteins in autoimmune diseases could be associated to 
deposition of complement components in host tissue (13). In this respect, complement 
proteins have been previously detected in human AAA wall (24,31,32). We observed 
that C3 protein levels were increased in tissue and tissue-conditioned media of AAA 
wall compared to healthy aortic wall, whereas C3 mRNA is similarly present in 
pathological and healthy wall in agreement with Hinterseher et al (24). But, 
Hinterseher et al did not show C3 staining in the thrombus (24). In contrast, we have 
shown that human AAA thrombus display an intense extracellular staining, along 
with increased protein levels in tissue homogenates and tissue-conditioned media of 
ILT compared to wall. Differences between both immunohistological studies could be 
related to the different antibodies used. Furthermore, C3 in thrombus from acute 
myocardial infarction has been also observed (33). Since the liver is the major source 
of complement proteins in humans and low/undetectable C3 mRNA levels were 
observed in thrombus homogenates, the high extracellular levels of C3 observed in 
AAA thrombus should be associated to its retention from serum and subsequent 
activation. In this regard, high C9 immunostaining was also shown in acellular areas 
of the thrombus and wall compared to healthy wall. In agreement, Pagano et al 
showed C5B9 in the luminal side of the wall, whereas no staining was observed in 
healthy wall (32). Similarly, Tulamo et al also observed complement activation and 
C5B9 formation in the less cellular part of intracranial artery aneurysm wall (34). 
Finally, we showed intense C9 immunostaining associated to C3 deposition, 
suggesting complement activation in AAA thrombus.  
Complement activation involves the classical pathway (CP), the lectin pathway, the 
alternative pathway (AP) and the extrinsic pathway (13). The CP pathway can be 
activated by antibodies or by other stimulus such as CRP. The AP is part of the innate 
(non-antigen-specific) immune system and is important in antibody-independent 
defense against bacterial infection. The extrinsic pathway involves proteolytic 
degradation of C3 by proteases such as elastase and/or by phagocytes. Moreover, 
other components of the coagulation system such as plasmin could also participate in 
complement activation (16). In this respect, human AAA thrombus could be a 
privileged site for complement activation since proteases and PMNs are abundant in 
the ILT of AAA (6,7). When we analyzed C3 levels in AAA tissue and tissue-
conditioned media by western-blot, we observed proteolytic fragments of C3 in AAA 
thrombus and thrombus-conditioned media. Furthermore, these products of C3 
proteolysis and activation were increased when native C3 protein was coincubated 
with the luminal part of AAA, supporting that in vivo proteolysis of C3 protein could 
take place within the thrombus of AAA. In addition, C3c/C3dg levels were increased 
in AAA wall compared to healthy wall. These proteolytic products could participate 
in the shift from innate to adaptive immunity characteristic of the adventitial response 
in AAA (35). Finally, given that C3a is released in the initial step of the proteolytic 
processing of C3, C3a levels were assessed in AAA tissue and healthy wall. In 
agreement with the results obtained for C3, C3a was increased in conditioned media 
of ILT and wall compared to healthy aorta wall, further supporting proteolysis of C3 
in AAA tissue. C3aR mRNA is upregulated in AAA tissue (24), favoring the potential 
interaction with C3a in AAA and its functional consequences. In this respect, it is 
already described that the complement acts as a critical mediator of neutrophil 
recruitment in AAA mice lesions (32). Interestingly, we have observed that PMN 
chemotaxis induced by the ILT could be modulated by incubation with an antiC3 
antibody. Moreover, C3a has been involved in PMN respiratory burst (36). We have 
observed that NADPH-dependent ROS production is increased when fresh PMNs are 
incubated with ILT-conditioned media and this effect was prevented by C3 blockade. 
In any case, we should take into account that these functional activities of the 
thrombus could be also related to the presence of other factors such as tissue factor, 
clotting factors (e.g. Xa) or thrombin, among others. Thrombin is involved in the 
activation of the complement system further confirming a coordinated action of the 
coagulation and complement systems (16). Interestingly, both systems have been 
associated with innate immunity into what Engelmann and Massberg recently 
described as immunothrombus (37). Thrombin also modulates fibrinolysis by 
activating the plasma carboxypeptidase, thrombin-activatable procarboxypeptidase B 
(pCPB). In this respect, enhanced AAA formation in pCPB−/− mice was observed 
associated to plasmin generation (38). On the whole, all this data suggest that 
complement activation by proteases present in the thrombus could contribute to AAA 
pathogenesis. 
Several studies have recently demonstrated that genetic modification of different 
mediators of the complement pathway could reduce experimental AAA formation 
(29, 32). However, complement activation is modulated by several complement 
inhibitors (e.g. CD59, vitronectin). In this respect, Tulamo et al showed a differential 
distribution of complement inhibitors in different areas of the wall of intracranial 
artery aneurysms. These data suggest that a disturbed complement regulation is 
associated with an increased susceptibility to complement activation and 
inflammation, and maybe also cell loss (34). In our previous study, vitronectin was 
shown to be down-regulated in tissue of ruptured AAA compared with non-ruptured 
AAA (39). Finally, deficiency of CD59 accelerated, whereas transgenic 
overexpression of human CD59 attenuated, the progression of experimental AAA 
(40). At the therapeutic level, antiC5 blockade was able to reverse atherosclerosis 
associated to decrease complement deposition (41). Since atherosclerosis and AAA 
share some pathological mechanisms, it could be interesting to address whether the 
therapeutic modulation of complement activators or inhibitors may have a protective 
role in AAA progression.  
On the whole, the decrease of systemic C3 concentration and activity in the 
later stages of AAA associated to local complement retention, consumption and 
proteolysis in the thrombus could induce PMN activation playing a detrimental role in 
AAA. Future studies targeting complement activation could be an attractive 
therapeutic strategy to prevent AAA progression. 
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FIGURE LEGENDS 
Figure 1. Ingenuity Pathway Analysis of identified proteins by LC-MS/MS.  
A.- The bar graphic shows the canonical pathways distribution represented by gene 
enrichment. Ratios show the number of genes associated to each pathway found in 
our experiment respect the human genome database. Fisher’s exact test provides p-
values <0.05 for the 7 most abundant canonical pathways.  
B.- Detailed inspection of the complement system cascade, where proteins identified 
by MS in AAA-tissue conditioned media are represented in grey colour. Protein 
groups or complex are yellow encircled, and receptors of different complement 
components are represented at the bottom of the figure. 
Figure 2. Systemic C3 concentration and activity in AAA patients. 
C3 concentration (A) and activity (B) in plasma of small AAA patients (n=26) an 
large AAA patients (n=39). Correlation of C3 concentration (C) and activity (D) with 
aortic size. 
Figure 3. Local complement retention in AAA tissue. 
Immunohistochemistry of C3 in thrombus (A), wall (C) and Healthy wall (D). 
Negative control (non-specific IgG) (B). C3 (E) and C9 (F) immunostaining is 
performed in serial sections of AAA thrombus. Magnification 20x. (inset: 120x, 
showing areas with PMNs) 
Figure 4. Local complement activation in AAA tissue and tissue-conditioned 
media. 
A.- Representative western blot of C3 in tissue homogenates of human AAA 
thrombus (T), pathological wall (W=media+adventitia) and healthy wall 
(H=media+adventitia).  
B.- Representative western blot of C3 in tissue conditioned media of human AAA 
thrombus (T), pathological wall (media, M, and adventitia, ADV) and healthy wall 
(media, HM, and adventitia, HADV).  
C.- Representative western blot of C3 in tissue conditioned media of human AAA 
pathological wall (media, M) and thrombus (T) and healthy wall (H). Fragments of 
C3 (C3dg, C3c, C3b, iC3b) or native C3 purified as described (20). 
D.- Representative western blot of C3 in thrombus conditioned media incubated with 
native C3. Arrows indicated proteolytic fragments of C3. 
Figure 5.-Role of complement activation in AAA thrombus-induced chemotaxis. 
A.- Elisa of C3a in tissue-conditioned media of human AAA thrombus (T, n=10), 
pathological wall [media (M, n=10) and adventitia (ADV, n=10)] and healthy wall 
[media (HM, n=10) and adventitia (HADV, n=10)]. * and †	p<0.001 for T vs M and 
ADV and M and ADV vs HM and HADV, respectively.  
B.- Chemotaxis assay showing  PMN migration towards the Thrombus (T), Thrombus 
preincubated with antiC3 (T+antiC3 at 1:100 or 1:10 dilution), Thrombus 
preincubated with anti-IgG (T+IgG, for non-specific chemotaxis). *p<0.001 for 
antiC3 vs T.  
C.- NADPH-dependent ROS production in PMNs stimulated during 2 min with 
Thrombus conditioned media, Thrombus preincubated with antiC3 (T+antiC3 at 
1:100 or 1:10 dilution) or Thrombus preincubated with  anti-IgG (T+IgG). *p<0.05 
for antiC3 vs T.  
Table 1.- Clinical characteristics of AAA patients  
a) First cohort 
 Small AAA (n=62) Large AAA (n=28) 
Sex (male/female) 62/0 28/0 
Age (years±SD) 69.9±6.7 73.4±6.6 
Dyslipidaemia (%) 56.5 37 
Current smoking (%) 37.1 42.9 
Diabetes (%) 19.4 3.6 
Hypertension (%) 64.5 64.3 
Heart disease (%) 32.3 21.4 
 
b) Second cohort 
 
 Small AAA (n=26) Large AAA (n=39) 
Sex (male/female) 24/2 37/2 
Age (years±SD) 79±5 70±10 
Dyslipidaemia (%) 46 53 
Current smoking (%) 15 30 
Diabetes (%) 30 7 
Hypertension (%) 73 46 




Clinical and pathophysiological evidences support that Intraluminal Thrombus (ILT) 
plays a role in evolution of Abdominal Aortic Aneurysms (AAA). ILT and wall 
conditioned-media were analyzed using a proteomic approach. Global pathways 
analysis of identified peptides/proteins highlighted that complement system 
components were highly enriched in AAA tissue-conditioned media. This could be 
related to its trapping from the blood (since decreased complement C3 concentration 
was associated to later stages of AAA in three different cohorts) and/or by increased 
proteolytic activation (as C3 fragments were observed in ILT). The functional 
consequences of complement retention and activation in AAA thrombus are related to 
increased PMN chemotaxis and ROS production, main mechanisms involved in AAA 
progression. Our data support an important role of complement activation not only in 
the initial phases of AAA formation (as demonstrated in experimental models of 
AAA) but also in human AAA progression associated to PMN recruitment and 
activation in ILT.  
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Figure	  1.	  Ingenuity	  Pathway	  Analysis	  of	  iden8fied	  proteins	  by	  LC-­‐MS/MS.	  	  
A.-­‐	  The	  bar	  graphic	  shows	  the	  canonical	  pathways	  distribu8on	  represented	  by	  gene	  
enrichment.	  Ra8os	  show	  the	  number	  of	  genes	  associated	  to	  each	  pathway	  found	  in	  our	  
experiment	  respect	  the	  human	  genome	  database.	  Fisher’s	  exact	  test	  provides	  p-­‐values	  
<0.05	  for	  the	  7	  most	  abundant	  canonical	  pathways.	  	  
B.-­‐	  Detailed	  inspec8on	  of	  the	  complement	  system	  cascade,	  where	  proteins	  iden8fied	  by	  MS	  
in	  AAA-­‐8ssue	  condi8oned	  media	  are	  represented	  in	  grey	  colour.	  Protein	  groups	  or	  complex	  
are	  yellow	  encircled,	  and	  receptors	  of	  different	  complement	  components	  are	  represented	  at	  
the	  boLom	  of	  the	  figure.	  
p<0.01 
A 
Figure	  2.	  Systemic	  C3	  concentra8on	  and	  ac8vity	  in	  AAA	  pa8ents.	  
C3	  concentra8on	  (A)	  and	  ac8vity	  (B)	  and	  in	  plasma	  of	  small	  AAA	  pa8ents	  (n=26)	  an	  large	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Figure	  3.	  Local	  complement	  reten8on	  in	  AAA	  8ssue.	  
Immunohistochemistry	  of	  C3	  in	  AAA	  thrombus	  (A),	  AAA	  wall	  (C),	  healthy	  wall	  (D).	  (B)	  
Nega8ve	  control	  of	  C3	  in	  AAA	  trhombus	  (IgG).	  Immunostaining	  of	  C3	  (E)	  and	  C9	  (F)	  in	  serial	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Figure	  4.	  Local	  complement	  ac8va8on	  in	  AAA	  8ssue.	  
A.-­‐	  Representa8ve	  western	  blot	  of	  C3	  in	  8ssue	  homogenates	  of	  human	  AAA	  thrombus	  (T),	  
pathological	  wall	  (W=	  media+adven88a)	  and	  healthy	  wall	  (H=media+adven88a).	  	  
B.-­‐	  Representa8ve	  western	  blot	  of	  C3	  in	  8ssue	  condi8oned	  media	  of	  human	  AAA	  thrombus	  
(T),	  pathological	  wall	  (media,	  M,	  and	  adven88a,	  ADV)	  and	  healthy	  wall	  (media,	  HM,	  and	  
adven88a,	  HADV).	  	  
C.-­‐	  Representa8ve	  western	  blot	  of	  C3	  in	  8ssue	  condi8oned	  media	  of	  human	  AAA	  pathological	  
wall	  (media,	  M)	  and	  thrombus	  (T)	  and	  healthy	  wall	  (H).	  Fragments	  of	  C3	  (C3dg,	  C3c,	  C3b,	  
iC3b)	  or	  na8ve	  C3	  purified	  as	  described	  (19).	  
D.-­‐Representa8ve	  western	  blot	  of	  C3	  in	  thrombus	  condi8oned	  media	  incubated	  with	  na8ve	  
C3.	  Arrows	  indicated	  proteoly8c	  fragments	  of	  C3.	  
C 
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Figure	  5.-­‐Role	  of	  complement	  ac8va8on	  in	  AAA	  thrombus-­‐induced	  PMN	  chemotaxis	  and	  
ac8va8on.	  	  
A.-­‐	  Elisa	  of	  C3a	  in	  8ssue-­‐condi8oned	  media	  of	  human	  AAA	  thrombus	  (T,	  n=10),	  pathological	  
wall	  [media	  (M,	  n=10)	  and	  adven88a	  (ADV,	  n=10)]	  and	  healthy	  wall	  [media	  (HM,	  n=10)	  and	  
adven88a	  (HADV,	  n=10)].	  *	  and	  †	  p<0.001	  for	  T	  vs	  M	  and	  ADV	  and	  M	  and	  ADV	  vs	  HM	  and	  
HADV,	  respec8vely.	  	  	  B.-­‐	  Chemotaxis	  assay	  showing	  	  PMN	  migra8on	  towards	  the	  Thrombus	  
(T),	  Thrombus	  preincubated	  with	  an8C3	  (T+an8C3	  at	  1:100	  or	  1:10	  dilu8on)	  or	  Thrombus	  
preincubated	  with	  an8-­‐IgG	  (T+IgG,	  for	  non-­‐specific	  chemotaxis).	  *p<0.001	  for	  an8C3	  vs	  T.	  	  	  
C.-­‐	  NADPH-­‐dependent	  ROS	  produc8on	  in	  PMNs	  s8mulated	  during	  2	  min	  with	  Thrombus	  
condi8oned	  media,	  Thrombus	  preincubated	  with	  an8C3	  (T+an8C3	  at	  1:100	  or	  1:10	  dilu8on)	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